Actively Recruiting
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Led by Jacobio Pharmaceuticals Co., Ltd. · Updated on 2026-01-16
294
Participants Needed
4
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors
CONDITIONS
Official Title
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided written informed consent
- 18 years of age or older at the time of consent
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors unsuitable for curative treatments
- Presence of KRAS alterations in tumors
- Agreement to provide an archived tumor sample
- Life expectancy of at least 3 months
- ECOG performance status of 0 or 1
- At least one measurable tumor lesion per RECIST v1.1 criteria
You will not qualify if you...
- Unable to swallow oral medications or having gastrointestinal issues affecting drug absorption
- Prior treatment with KRAS G12C, KRAS G12D, or pan/multi-KRAS inhibitors
- Known serious allergy to JAB-23E73 or its ingredients
- Presence of primary central nervous system tumors
- Uncontrolled pleural effusion, pericardial effusion, or ascites needing frequent drainage or medical intervention
- QT interval longer than 470 milliseconds
- Left ventricular ejection fraction 50% or lower as measured by ECHO or MUGA
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
2
Washington University
St Louis, Missouri, United States, 63110
Actively Recruiting
3
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Actively Recruiting
4
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Actively Recruiting
Research Team
J
Jacobio Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here